{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:30Z","timestamp":1790383830746,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,31]]},"DOI":"10.7759\/cureus.81505","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T13:34:40Z","timestamp":1743428080000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Use of Dalbavancin in a United States Tertiary Referral Center"],"prefix":"10.7759","author":[{"given":"James","family":"Polega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudita","family":"Bhugra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Vanderhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"de Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Hassouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac298","article-title":"Outpatient versus inpatient intravenous antimicrobial therapy: a population-based observational cohort study of adverse events and costs","volume":"75","author":"Staples JA","year":"2022","unstructured":"Staples JA, Ho M, Ferris D, Hayek J, Liu G, Tran KC, Sutherland JM. Outpatient versus inpatient intravenous antimicrobial therapy: a population-based observational cohort study of adverse events and costs. Clin Infect Dis. 2022, 75:1921-9. 10.1093\/cid\/ciac298","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka L","year":"2020","unstructured":"Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel). 2020, 9:700. 10.3390\/antibiotics9100700","journal-title":"Antibiotics (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae177","article-title":"Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review","volume":"79","author":"Wolie ZT","year":"2024","unstructured":"Wolie ZT, Roberts JA, Gilchrist M, McCarthy K, Sime FB. Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review. J Antimicrob Chemother. 2024, 79:2083-102. 10.1093\/jac\/dkae177","journal-title":"J Antimicrob Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr MB","year":"2005","unstructured":"Dorr MB, Jabes D, Cavaleri M, et al.. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005, 55:ii25-30. 10.1093\/jac\/dki008","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of dalbavancin","volume":"61","author":"Molina KC","year":"2022","unstructured":"Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical pharmacokinetics and pharmacodynamics of dalbavancin. Clin Pharmacokinet. 2022, 61:363-74. 10.1007\/s40262-021-01088-w","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne MW","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015, 59:1849-55. 10.1128\/AAC.04550-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo U","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al.. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019, 6:ofy331. 10.1093\/ofid\/ofy331","journal-title":"Open Forum Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna","volume":"67","author":"Tobudic S","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al.. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis. 2018, 67:795-8. 10.1093\/cid\/ciy279","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza E","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, et al.. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018, 51:571-7. 10.1016\/j.ijantimicag.2017.11.008","journal-title":"Int J Antimicrob Agents"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae066","article-title":"Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs","volume":"6","author":"Bresges C","year":"2024","unstructured":"Bresges C, Bresges K, Hewitt C, Sharma S, Davies B. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs. JAC Antimicrob Resist. 2024, 6:dlae066. 10.1093\/jacamr\/dlae066","journal-title":"JAC Antimicrob Resist"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch S","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, et al.. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019, 81:210-4.","journal-title":"Int J Infect Dis"},{"key":"ref12","unstructured":"Drugs@FDA. FDA-approved drugs. (2025). Accessed: February 2025: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/idr14020032","article-title":"Evaluating the use of dalbavancin for off-label indications","volume":"14","author":"Taylor K","year":"2022","unstructured":"Taylor K, Williamson J, Luther V, et al.. Evaluating the use of dalbavancin for off-label indications. Infect Dis Rep. 2022, 14:266-72. 10.3390\/idr14020032","journal-title":"Infect Dis Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02393-9","article-title":"A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis","volume":"53","author":"Leanza GM","year":"2025","unstructured":"Leanza GM, Rando E, Frondizi F, et al.. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025, 53:15-23. 10.1007\/s15010-024-02393-9","journal-title":"Infection"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.11.018","article-title":"Efficacy and safety of dalbavancin in the treatment of gram-positive bacterial infections","volume":"24","author":"Wang Y","year":"2021","unstructured":"Wang Y, Wang J, Wang R, Li Y, Cai Y. Efficacy and safety of dalbavancin in the treatment of gram-positive bacterial infections. J Glob Antimicrob Resist. 2021, 24:72-80. 10.1016\/j.jgar.2020.11.018","journal-title":"J Glob Antimicrob Resist"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.37201\/req\/012.2024","article-title":"Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience","volume":"37","author":"Brandariz-N\u00fa\u00f1ez D","year":"2024","unstructured":"Brandariz-N\u00fa\u00f1ez D, Luances-Rodr\u00edguez A, Feijoo-Vilanova P, Guti\u00e9rrez-Urb\u00f3n JM, Ramudo-Cela L, Mart\u00edn-Herranz MI, Margusino-Frami\u00f1\u00e1n L. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience. Rev Esp Quimioter. 2024, 37:334-40. 10.37201\/req\/012.2024","journal-title":"Rev Esp Quimioter"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111063","article-title":"Safety and efficacy of dalbavancin in real life: retrospective analysis of a large monocentric case series of patients treated for skin\/soft tissue and other difficult-to-treat infections","volume":"13","author":"Parruti G","year":"2024","unstructured":"Parruti G, Polilli E, Coladonato S, et al.. Safety and efficacy of dalbavancin in real life: retrospective analysis of a large monocentric case series of patients treated for skin\/soft tissue and other difficult-to-treat infections. Antibiotics (Basel). 2024, 13:1063. 10.3390\/antibiotics13111063","journal-title":"Antibiotics (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-024-01503-4","article-title":"The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach","volume":"13","author":"Ficinski M","year":"2024","unstructured":"Ficinski M, West J, Glassman S, et al.. The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach. Antimicrob Resist Infect Control. 2024, 13:149. 10.1186\/s13756-024-01503-4","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel JS","year":"2015","unstructured":"McDanel JS, Perencevich EN, Diekema DJ, et al.. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015, 61:361-7. 10.1093\/cid\/civ308","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/333432-real-world-use-of-dalbavancin-in-a-united-states-tertiary-referral-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T13:34:42Z","timestamp":1743428082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/333432-real-world-use-of-dalbavancin-in-a-united-states-tertiary-referral-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.81505","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}